Investor Presentaiton

Particulars¹ 3,943 2,134 Pharmaceuticals Segment Highlights - 9M'FY20 Revenue Specialty Pharma Geography Wise Revenue¹ 3,211 3,495 9M'FY19 9M'FY20 % Change 4,231 7% 2,233 5% CDMO 1,024 1,148 12% Generics Reported EBITDA Adjusted EBITDA 786 850 8% 98 106 378 341 256 289 1,087 1,127 4% India 1,095 1,192 9% North America Europe & Japan ROW Reported EBITDA Margin (%) Adjusted EBITDA Margin (%) 27.6% 26.6% 9M'FY19 9M'FY20 27.8% 28.2% ■ Pharmaceuticals revenue at Rs 4,231 Crore, increased 7% YoY • Growth in all key revenue segments with 5% growth in Specialty Pharma, 12% growth in CDMO and 8% growth in Generics Revenue from North America and ROW grew 9% YoY and 13% YoY, respectively, while that from Europe & Japan was lower by 10% YoY Specialty Pharma (53% of Pharma revenue) • CDMO Revenue increased 5% YoY to Rs 2,233 Crore Radiopharma revenue increased due to higher volumes in Ruby-Fill® and other key products Revenue growth witnessed in Allergy business led by higher volumes in venom and allergenic extracts and better prices • Revenue increased 12% YoY to Rs 1,148 Crore • Growth in CMO business led by strong demand witnessed from key customers, which was reflected by higher volumes as compared to 9M'FY19 API Revenue growth was due to better pricing in products like valsartan as compared to 9M'FY19 Generics Business witnessed lower volumes due to additional quality checks on all input raw materials to meet enhanced regulatory requirements Revenue growth of 8% YoY due to better prices in some products which was offset by lower volumes ■ Pharmaceuticals EBITDA at Rs 1,127 Crore up 4% YoY with a margin of 26.6% as compared to 27.6% in 9M'FY19. ■ Pharmaceuticals Adjusted EBITDA at Rs 1,192 Crore increased 9% YoY with a margin of 28.2% as compared to 27.8% in 9M'FY19 • One-off expenses of Rs 65 Crore related to related to site remediation, litigation expenses and penalties on non-supply R&D spent during 9M at Rs. 186 Crore - 4.4% to segment sales. R&D debited to P&L is Rs. 157 Crore - 3.7% to segment sales 1. All figures are in Rs Crore unless otherwise stated LIFESCIENCES

View entire presentation